Neurodegenerative diseases present some of the greatest challenges in medicine due to their complexity, heterogeneity, and the limited availability of reliable biomarkers and treatments. Join us for ...
Cognito Therapeutics Announces Presentation of New CSF Proteomic and EEG Biomarker Data for Spectris™ in Alzheimer’s Disease at CTAD 2025 Cognito Therapeutics, a clinical-stage medical device company ...
A fully automated plasma biomarker panel detected amyloid-beta (Aβ) positivity and monitored early amyloid accumulation in middle-aged cognitively unimpaired (CU) adults at risk for Alzheimer's ...
Global prevalence estimates show Alzheimer’s disease accounts for most dementia, with ~57 million people affected in 2021 and numbers projected to triple by 2050. People and health systems face rising ...
Brain-derived extracellular vesicle (EV) biomarkers represent a promising frontier for liquid biopsy development targeting the nervous system. They offer strong potential for enabling minimally ...
OTTAWA, Ontario — Looking for Alzheimer’s disease (AD) biomarkers in plasma instead of cerebrospinal fluid (CSF) is a simpler form of screening individuals for AD pathology and could result in earlier ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results